17.13 +0.08 (0.46%)
After hours: 4:11PM EDT
|Bid||17.05 x 21500|
|Ask||17.07 x 2900|
|Day's Range||16.75 - 18.50|
|52 Week Range||5.27 - 18.50|
|Beta (3Y Monthly)||0.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.81|
DUBLIN, Oct. 11, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced that data regarding the evaluation and rating of cellulite severity will be presented at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. The results indicate that the gender of a HCP does not appear to impact assessment of cellulite severity ratings.
"We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”
DUBLIN , Sept. 28, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its third-quarter 2018 financial results on November 8, 2018 and members of its senior management team will host ...
PLC (ENDP) on Friday said its Endo Pharmaceuticals Inc. unit is recalling two lots of the muscle relaxant Robaxin due to incorrect dosing information on the label that could lead to overdose. Endo said patients who follow the incorrect directions could experience significant drowsiness or dizziness that would put them at risk for falls or an overdose that could result in seizures, coma or death. An Endo spokeswoman said the recall, which affects about 2,856 bottles of tablets, was voluntary and precautionary, and that the company hasn’t received any reports of injuries or serious adverse reactions related to the issue.
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth ...
DUBLIN , Sept. 28, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® ...
NEW YORK, Sept. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Endo International Plc is halting its lawsuit against the U.S. Food And Drug Administration until the end of the year after the agency made new commitments on the regulation relating to the active ingredient in blood pressure medicine Vasostrict. Last month, the FDA proposed excluding three substances from a list of ingredients that could be used to manufacture compounded medications in bulk, including vasopressin, the active ingredient in Vasostrict. "We believe that a brief additional stay of our litigation is appropriate to allow FDA to complete its rulemaking process," Matthew Maletta, Endo's chief legal officer, said in a statement on Monday.
DUBLIN , Sept. 24, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it has agreed to an additional stay of its litigation against the U.S. Food and Drug Administration (FDA) ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding ENDP is favorable, with net inflows of $20.59 billion.
The Zacks Analyst Blog Highlights: Ingersoll-Rand, Endo International, Glanbia and Smurfit Kappa Group
Francis Chou, a well-regarded Canadian value investor, the founder of Chou Associates Management, and Morningstar Fund Manager of the Decade in 2004, was once just an ordinary immigrant in Canada with $200 in his pocket. Even though he is Chinese, he was born and raised in India, and came to Canada looking for a job. For […]
Ireland's growth in the past few years not only shows its resilience to the economic downturn in the EU but also makes it one of the most business-friendly destinations of the region.
The biotech sector has seen some year-to-date strength, as reflected by the nearly 11-percent advance in the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ). The upward momentum became more pronounced ...